RxDoctor Payments Data

Lacinda Butler

Women's Health · Jackson, TNNPI 1124015144

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.8% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $816, 4.9 times the $166 reported in 2021.

$1,894in general payments, 2019–2025

Across 85 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$369
  • Bayer$189
  • Daiichi Sankyo Inc.$186
  • Biogen$159
  • Mayne Pharma Commercial LLC$150
  • Exeltis, USA Inc.$121
  • plus $720 from 13 others

What the payments were for

  • Consulting fees$1759%
  • Food & beverage$1,71991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,894 in reported general payments places this provider in the 80th percentile of 202 women's health providers in Tennessee.

See all women's health providers in Tennessee

Medicare billing

Part B allowed, 2024
$36,087
Medicare patients
284
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$10,412
Estradiol56$1,538
Clorazepate Dipotassium15$1,189
ValacyclovirValacyclovir Hcl25$639
Ibandronate Sodium19$246
Betamethasone Valerate15$239
Fluconazole14$138
Alendronate Sodium35$111
Alprazolam25$101
Sertraline Hcl20$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$101$10,41211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 202 women's health providers in Tennessee.

Other women's health in Jackson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →